FDA partially halts Nurix Therapeutics’ cancer trial as it improves manufacturing process

The FDA is pausing patient enrollment and screening for Nurix Therapeutics’ Phase I clinical trial for a potential drug to treat B-cell malignancies in cancer patients.

The agency is halting the trial after Nurix told the FDA it is improving the manufacturing process of the potential…
Click here to view original post